Product Description: Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Alexander Röth, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334.
CAS Number: 2049079-64-1
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Inflammation/Immunology; Cardiovascular Disease
Solubility: H2O
Target: Complement System